Botanix Pharmaceuticals Ltd - Asset Resilience Ratio
Botanix Pharmaceuticals Ltd (BOT) has an Asset Resilience Ratio of 6.42% as of June 1996. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1992–2019)
This chart shows how Botanix Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Botanix Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$3.66 Million | 6.42% |
| Total Liquid Assets | AU$3.66 Million | 6.42% |
Asset Resilience Insights
- Limited Liquidity: Botanix Pharmaceuticals Ltd maintains only 6.42% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Botanix Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio
Compare Botanix Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Zelluna ASA
OL:ZLNA |
Biotechnology | 75.65% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Botanix Pharmaceuticals Ltd (1992–2019)
The table below shows the annual Asset Resilience Ratio data for Botanix Pharmaceuticals Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-06-30 | 0.00% | AU$0.00 | AU$5.20 Million | -- |
| 2018-06-30 | 0.12% | AU$20.44K | AU$17.71 Million | -- |
| 2017-06-30 | 0.00% | AU$0.00 | AU$5.91 Million | -- |
| 2016-06-30 | 0.00% | AU$0.00 | AU$3.70 Million | -- |
| 1996-06-30 | 6.42% | AU$3.66 Million | AU$57.05 Million | +3.42pp |
| 1995-06-30 | 3.00% | AU$2.04 Million | AU$68.16 Million | -0.61pp |
| 1994-06-30 | 3.61% | AU$1.75 Million | AU$48.56 Million | +0.27pp |
| 1993-06-30 | 3.34% | AU$1.27 Million | AU$38.03 Million | -2.04pp |
| 1992-06-30 | 5.38% | AU$1.40 Million | AU$25.92 Million | -- |
About Botanix Pharmaceuticals Ltd
Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment o… Read more